| |
|
|
|
IQPC, San Francisco, CA
Sept. 21-23, 2009
IQPC’s Metabolic Diseases Program is designed to bring together valuable case studies, lessons learned and best practices in the forms of panel session in drug discovery and development. The specific focus of the program include: adapting the new cardiovascular study requirement for diabetic drugs – where do you start or should you abandon it. Inflammation aspects metabolic diseases, selecting best clinical model – compare and contract, what are the common drawbacks. Speaking companies include Pfizer, Johnson and Johnson, Bristol Myers Squibb, Arena Pharmaceuticals, Amgen, Isis Pharmaceuticals, Syndexa Pharmaceuticals, Exelixis, Vivus and others. Visit www.iqpc.com/us/metabolic for more information.
|
|
|
|
|
|
|
|
Organized by:
|
|
IQPC |
|
|
Invited Speakers:
|
|
Featuring A Distinguished Speaker Faculty From:- Pfizer
- Johnson & Johnson
- Arena Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Orexigen Therapeutics
- Syndexa
- Pharmaceuticals
- Exelixis
- Amylin
- Pharmaceuticals
- Vivus
- Merck
- Novo Nordisk
- Sirtris Pharmaceuticals,
- a GSK Company
- Zafgen
- Roche
- Isis Pharmaceuticals
- And more!
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
September 10, 2009
|
|
|
|
|
|
|
|
Registration:
|
|
www.iqpc.com/us/metabolic
|
|
|
E-mail:
|
|
eduardo.becerra@iqpc.com
|
|
|
|
|
|
|
|
|